Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
about
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsSystems biology of cisplatin resistance: past, present and futureCombination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.Decreased Poly(ADP-Ribose) Polymerase 1 Expression Attenuates Glucose Oxidase-Induced Damage in Rat Cochlear Marginal Strial Cells.Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinomaThe protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Predictive biomarkers for cancer therapy with PARP inhibitors.Platinum-based drugs: past, present and future.PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.PARPi potentiates with current conventional therapy in MLL leukemia.Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
P2860
Q26852274-2AD3363E-8CE8-4FC9-8BDB-4AFBC05E41DAQ26863585-348DE95C-79FB-4949-87D4-C4012BA61D06Q33798999-F91755AD-B343-4373-812D-EAA6E08D5C80Q36094171-A5231F9D-D618-4F4A-9D62-D1E160153138Q37377837-90D05F9F-0D17-4DFD-944D-F256FD1A6784Q37687452-E59BEE76-AC37-4914-9F7C-A953B952B1ADQ37689423-C47C665F-B030-45B5-B52F-A27E6B8284C2Q37729428-19516054-F5BE-4203-86DA-32346E7D2ED3Q38137764-BE606025-EE10-48C2-8C29-C0B886C9C846Q38737115-40688086-F0CD-4AAF-86B4-B85AEFA15A46Q38792223-B6831ACC-573F-4383-9474-FBDA79A155ADQ42373962-65384C60-B5A5-42D1-B99E-466EB1B59329Q42739081-4B0B7330-0938-4617-A4A1-D09CF4028C87Q47833710-6FAFE7E2-D61A-4467-B731-126510AD8B9FQ52604402-06148B14-B152-4DFF-8AA8-A791ED2762ED
P2860
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Synergistic interaction betwee ...... in non-small cell lung cancer.
@en
type
label
Synergistic interaction betwee ...... in non-small cell lung cancer.
@en
prefLabel
Synergistic interaction betwee ...... in non-small cell lung cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
Synergistic interaction betwee ...... in non-small cell lung cancer.
@en
P2093
Catherine Brenner
David P Enot
Delphine Lissa
Ilio Vitale
Judith Michels
Ken A Olaussen
Maria Castedo
Pauline Garcia
P2860
P304
P356
10.4161/CC.24034
P577
2013-02-21T00:00:00Z